116 related articles for article (PubMed ID: 32439236)
21. Assessment of the correlation between serum prolidase and alpha-fetoprotein levels in patients with hepatocellular carcinoma.
Ilikhan SU; Bilici M; Sahin H; Akca AS; Can M; Oz II; Guven B; Buyukuysal MC; Ustundag Y
World J Gastroenterol; 2015 Jun; 21(22):6999-7007. PubMed ID: 26078578
[TBL] [Abstract][Full Text] [Related]
22. Serum Beta-2 Microglobulin: a Possible Marker for Disease Progression in Egyptian Patients with Chronic HCV Related Liver Diseases.
Ouda SM; Khairy AM; Sorour AE; Mikhail MN
Asian Pac J Cancer Prev; 2015; 16(17):7825-9. PubMed ID: 26625805
[TBL] [Abstract][Full Text] [Related]
23. Risk of hepatocellular carcinoma in HBV cirrhotic patients assessed by the combination of miR-122, AFP and PIVKA-II.
Caviglia GP; Abate ML; Gaia S; Petrini E; Bosco C; Olivero A; Rosso C; Ciancio A; Pellicano R; Saracco GM; Rizzetto M; Smedile A
Panminerva Med; 2017 Dec; 59(4):283-289. PubMed ID: 28650134
[TBL] [Abstract][Full Text] [Related]
24. Plasma proteosome level as a potential marker for hepatocellular carcinoma.
Salama HM; Abdel-Haleem H; Taha FM; Abdel-Azeez RA; Marzaban RN; El-Nahaas SM; Darwish T
Arab J Gastroenterol; 2013 Sep; 14(3):87-93. PubMed ID: 24206735
[TBL] [Abstract][Full Text] [Related]
25. Prognostic significance of three hepatitis markers (p53 antibodies, vascular endothelial growth factors and alpha fetoprotein) in patients with hepatocellular carcinoma.
Gadelhak NA; Gadelhak SA; El-Morsi DA; Abdelaziz MM; Abbas AT; El-Emshaty HM
Hepatogastroenterology; 2009; 56(94-95):1417-24. PubMed ID: 19950803
[TBL] [Abstract][Full Text] [Related]
26. Activity of serum angiotensin-converting enzyme as a tumour marker of hepatocellular carcinoma.
Kardum D; Huskic J; Fabijanic D; Banic M; Buljevac M; Kujundzic M; Loncar B
Eur J Gastroenterol Hepatol; 1999 Nov; 11(11):1209-13. PubMed ID: 10563528
[TBL] [Abstract][Full Text] [Related]
27. Diagnostic significance of plasma osteopontin in hepatitis C virus-related hepatocellular carcinoma.
Abu El Makarem MA; Abdel-Aleem A; Ali A; Saber R; Shatat M; Rahem DA; Sayed D
Ann Hepatol; 2011; 10(3):296-305. PubMed ID: 21677331
[TBL] [Abstract][Full Text] [Related]
28. Plasma nuclear factor kappa B and serum peroxiredoxin 3 in early diagnosis of hepatocellular carcinoma.
Ismail S; Mayah W; Battia HE; Gaballah H; Jiman-Fatani A; Hamouda H; Afifi MA; Elmashad N; Saadany SE
Asian Pac J Cancer Prev; 2015; 16(4):1657-63. PubMed ID: 25743848
[TBL] [Abstract][Full Text] [Related]
29. Lipocalin-2: A novel diagnostic marker for hepatocellular carcinoma.
Barsoum I; Elgohary MN; Bassiony MAA
Cancer Biomark; 2020; 28(4):523-528. PubMed ID: 32568173
[TBL] [Abstract][Full Text] [Related]
30. Serum DLK1 is a potential prognostic biomarker in patients with hepatocellular carcinoma.
Li H; Cui ML; Chen TY; Xie HY; Cui Y; Tu H; Chen FH; Ge C; Li JJ
Tumour Biol; 2015 Nov; 36(11):8399-404. PubMed ID: 26018510
[TBL] [Abstract][Full Text] [Related]
31. The role of chemokine CC ligand 20 in patients with liver cirrhosis and hepatocellular carcinoma.
Soliman HH; Nagy H; Kotb N; Alm El-Din MA
Int J Biol Markers; 2012 Jul; 27(2):e125-31. PubMed ID: 22388957
[TBL] [Abstract][Full Text] [Related]
32. The Expressions of CD44, CD90 and Alpha Fetoprotein Biomarkers in Indonesian Patients with Advanced Liver Disease: an Observational Study.
Mustika S; Wijaya H; Pratomo B
Acta Med Indones; 2019 Apr; 51(2):137-144. PubMed ID: 31383828
[TBL] [Abstract][Full Text] [Related]
33. Clinical significance and diagnostic value of serum dickkopf-1 in patients with hepatocellular carcinoma.
Fouad YM; Mohamed HI; Kamal EM; Rasek MA
Scand J Gastroenterol; 2016 Sep; 51(9):1133-7. PubMed ID: 27161933
[TBL] [Abstract][Full Text] [Related]
34. Could serotonin be a potential marker for hepatocellular carcinoma? A prospective single-center observational study.
Abdel-Razik A; Elhelaly R; Elzehery R; El-Diasty A; Abed S; Elhammady D; Tawfik A
Eur J Gastroenterol Hepatol; 2016 May; 28(5):599-605. PubMed ID: 26741637
[TBL] [Abstract][Full Text] [Related]
35. Serum biomarkers for early detection of hepatocellular carcinoma associated with HCV infection in egyptian patients.
Zekri AR; Youssef AS; Bakr YM; Gabr RM; El-Rouby MN; Hammad I; Ahmed EA; Marzouk HA; Nabil MM; Hamed HA; Aly YH; Zachariah KS; Esmat G
Asian Pac J Cancer Prev; 2015; 16(3):1281-7. PubMed ID: 25735368
[TBL] [Abstract][Full Text] [Related]
36. Serum VEGF as a tumor marker in patients with HCV-related liver cirrhosis and hepatocellular carcinoma.
Mukozu T; Nagai H; Matsui D; Kanekawa T; Sumino Y
Anticancer Res; 2013 Mar; 33(3):1013-21. PubMed ID: 23482775
[TBL] [Abstract][Full Text] [Related]
37. Validity of alpha fetoprotein for diagnosis of hepatocellular carcinoma in cirrhosis.
Sarwar S; Khan AA; Tarique S
J Coll Physicians Surg Pak; 2014 Jan; 24(1):18-22. PubMed ID: 24411536
[TBL] [Abstract][Full Text] [Related]
38. Clinical utility of simultaneous measurement of serum high-sensitivity des-gamma-carboxy prothrombin and Lens culinaris agglutinin A-reactive alpha-fetoprotein in patients with small hepatocellular carcinoma.
Sassa T; Kumada T; Nakano S; Uematsu T
Eur J Gastroenterol Hepatol; 1999 Dec; 11(12):1387-92. PubMed ID: 10654799
[TBL] [Abstract][Full Text] [Related]
39. Serum fucosylated paraoxonase 1 as a potential glycobiomarker for clinical diagnosis of early hepatocellular carcinoma using ELISA Index.
Zhang S; Jiang K; Zhang Q; Guo K; Liu Y
Glycoconj J; 2015 May; 32(3-4):119-25. PubMed ID: 25702281
[TBL] [Abstract][Full Text] [Related]
40. Comparison of AFP-L3 and p53 Antigen Concentration with Alpha-Fetoprotein as Serum Markers for Hepatocellular Carcinoma.
Abdel-Aziz MM; Elshal MF; Abass AT; El-Kafrawy S; Ezzat S; Abdel-Wahab M
Clin Lab; 2016; 62(6):1121-9. PubMed ID: 27468575
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
